1 Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain

2 CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain

3 Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Infectious Diseases Research Group, University Hospital Virgen del Rocio, Sevilla, Spain

4 Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain

5 Clinical Medicine Department, Universidad Miguel Hernández, Alicante, Spain

6 Division of Infectious Diseases, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

7 Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Barcelona, Spain

8 Consulta de seguimiento de VIH-Medicina Interna, Hospital Álvaro Cunqueiro, Vigo, Spain

9 National Centre of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain

10 Clinic Biostatistic Unit, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

11 CIBERESP, Universidad de Alcalá, Alcalá de Henares, Spain

12 Departamento de Medicina, IBiS, Universidad de Sevilla, Hospital Universitario Virgen de Valme, Sevilla, Spain

13 HIV Unit, University Hospital 12 de Octubre–Imas12, Madrid, Spain

14 Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

15 Infectious Diseases Unit, Hospital Universitario General de Santa Lucía, Cartagena, Spain

16 Infectious Diseases Unit, Hospital Universitario de Jaén, Jaén, Spain

17 Department of Infectious Diseases, National Referal Centre for Tropical Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML and PDF versions of this article on the journal’s website (www.dcrjournal.com).

Funding/Support: The RIS cohort (CoRIS) is supported by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional.

Financial Disclosure: A.C.U. has done consulting work for Gilead Sciences, Janssen Cilag, Merck Sharp and Dohme, ViiV Healthcare; reports grants and personal fees from ViiV Healthcare and personal fees from Gilead, Janssen, and Merck; and reports support for attending meetings and/or travel from ViiV Healthcare, Gilead, Janssen, and Merck, all of them unrelated to the submitted work. M.R. received a grant from Gilead Sciences unrelated to the submitted work. D.R.-C. reports personal fees from Gilead Sciences Inc; nonfinancial support and personal fees from Janssen Cilag; grants and personal fees from ViiV Healthcare, outside the submitted work; and reports support from Gilead Sciences Inc and from ViiV Healthcare, outside the submitted work. J.M.-S. reports payment or honoraria for lectures, presentations, speakers bureaus, or educational events from Gilead Sciences, MSD, ViiV Healthcare, and Jannsen Cilag; and reports support for attending meetings and/or travel, all of them unrelated to the submitted work. J.A.P.-M. reports grants from ViiV Healthcare and Gilead Sciences; consulting fees from ViiV Healthcare; and support for attending meetings and/or travel from ViiV Healthcare and Gilead Sciences, all of them unrelated to the submitted work.

Correspondence: José A. Perez-Molina, M.D., Ph.D., Carretera Colmenar Viejo km 9, 28034 Madrid, Spain. E-mail: [email protected]; Elena Sendagorta Cudós, Ph.D., Paseo de la Castellana 261, 28046 Madrid, Spain. E-mail: [email protected]